Researchers have identified an enzyme that is metabolic and a pathway in a subset of triple-negative breast cancer (TNBC) patients They hope that this pathway could serve as a biomarker to determine which patients are eligible for targeted treatment.
Triple-negative breast cancer (TNBC) (TNBC), which is the most aggressive form and is the most common form of breast cancer that affects young Black women. The disease is rapidly spreading and has high mortality as well as Relapse rates.
Our work shows that a fraction of TNBC with high expression of dihydrolipoamide S-Succinyltransferase (DLST), a metabolic enzyme, in their tumor cells depends on the TCA-cycle for survival. Thus, DLST expression could serve as a biomarker to determine TNBC patients to receive CPI-613, a medication currently being tested in clinical trials for treating other cancers.”
Hui Feng MD, PhD, corresponding writer as well as associate professor of pharmacology and medicine at Boston University School of Medicine
Researchers in the Feng lab examined human TNBC samples and human cell lines including those injected into animals to define the role of DLST to TNBC pathogenesis. Comprehensive molecular and biochemical assays were also utilized to understand the molecular and metabolic properties of TNBC cells.
Feng claimed that CPI-613 may be beneficial to a small portion of patients suffering from aggressive tumors due to the current challenges in the treatment of triple negative breast cancer.
Shen, N., and. (2021) DLST-dependence is the reason for the metabolic heterogeneity of TCA-cycle usage among triple negative breast cancer . Communications Biology. doi.org/10.1038/s42003-021-02805-8.
Content Source: https://www.news-medical.net/news/20211116/New-metabolic-vulnerabilities-of-subsets-of-triple-negative-breast-cancer-discovered.aspx